(1-(2-Morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone | 166599-76-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (1-(2-Morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone
• 英文别名: (4-methoxynaphthalen-1-yl)-[1-(2-morpholin-4-ylethyl)indol-3-yl]methanone
• CAS: 166599-76-4
• 化学式: C₂₆H₂₆N₂O₃
• 分子量: 414.5
• InChiKey: QWHSUXWDDKWTOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.7
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN
  申请人：The Regents of the University of California

  公开号：US20150239859A1

  公开（公告）日：2015-08-27

  Peripherally acting cannabinoid agonist compounds, pharmaceutical compositions, and methods of using them are presented.

  本文介绍了外周作用的大麻素激动剂化合物、制药组合物以及使用它们的方法。
• Verwendung von Agonisten des zentralen Cannabinoid-Rezeptors CB1
  申请人：Bayer HealthCare AG

  公开号：EP0860168B1

  公开（公告）日：2007-08-08
• US9656981B2
  申请人：——

  公开号：US9656981B2

  公开（公告）日：2017-05-23
• [EN] TRANSDERMAL DELIVERY OF CANNABIDIOL<br/>[FR] ADMINISTRATION TRANSDERMIQUE DE CANNABIDIOL
  申请人：PIKE THERAPEUTICS INC 1219014 B C LTD

  公开号：WO2021074790A1

  公开（公告）日：2021-04-22

  Provided is a transdermal drug delivery system comprising cannabidiol, or its salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.
• [EN] TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN<br/>[FR] FORMULATIONS PHARMACEUTIQUES TRANSDERMIQUES ET/OU TOPIQUES COMPRENANT DU CANNABIDIOL ET/OU DU TÉTRAHYDROCANNABINOL POUR LE TRAITEMENT DE LA DOULEUR CHRONIQUE
  申请人：PIKE THERAPEUTICS INC

  公开号：WO2021214545A1

  公开（公告）日：2021-10-28

  The current application relates to a transdermal or topical pharmaceutical formulation comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of chronical pain with reduced side effects in the patient. The transdermal or topical formulation can also be used for the treatment of various symptoms associated with multiple sclerosis (MS).